Manikomycin Antibiotic Targets Bacterial Ribosome E-site
Scientists have discovered a new antibiotic, manikomycin, which uses a unique mechanism to fight bacteria. This discovery could lead to new ways to combat drug-resistant infections.
Source: Nature NewsA new natural depsipeptide antibiotic, named manikomycin, has been identified from the bacterium Streptomyces rimosus. This discovery was published online in Nature on June 3, 2026. Researchers used improved fractionation strategies to find this antibiotic, which has a previously unseen chemical structure. Manikomycin works by specifically targeting the E-site of the bacterial large ribosomal subunit. The ribosome is a crucial part of bacteria responsible for protein synthesis. By binding to the E-site, manikomycin disrupts this process, effectively stopping bacterial growth. This novel mechanism of action makes manikomycin a promising candidate for developing new drugs against antibiotic-resistant bacteria, which pose a significant global health threat.
This discovery is important for competitive exams, especially for topics under Science & Technology in UPSC GS Paper III and SSC General Science. It highlights advancements in antibiotic research and the fight against antimicrobial resistance (AMR). Aspirants should understand the mechanism of action of new drugs and the significance of novel compounds from natural sources. This topic connects to biotechnology, public health, and the challenges of drug development.
- Manikomycin is a natural depsipeptide antibiotic.
- It was discovered from the bacterium Streptomyces rimosus.
- The antibiotic targets the E-site of the bacterial large ribosomal subunit.
- The discovery was published in Nature on June 3, 2026.
- Manikomycin represents a new class of antibiotics with a unique mechanism.
- Its action disrupts bacterial protein synthesis.
Depsipetides are a class of peptides where one or more amide bonds are replaced by ester bonds. Many depsipeptides are produced by microorganisms and have significant biological activities, including antibiotic, antiviral, and anticancer properties. They are often cyclic and can be highly stable, making them attractive for drug development.
The ribosome is a complex molecular machine found within all living cells that serves as the site of biological protein synthesis (translation). Ribosomes link amino acids together in the order specified by messenger RNA (mRNA) molecules. Bacterial ribosomes are structurally different from human ribosomes, making them a common target for antibiotics.
Streptomyces rimosus is a species of Gram-positive bacteria belonging to the genus Streptomyces. These bacteria are well-known for their ability to produce a wide range of bioactive compounds, including many important antibiotics. S. rimosus is notably the source of the antibiotic oxytetracycline and now, manikomycin.
UPSC and SSC often ask about new scientific discoveries, especially in medicine and biotechnology, and their implications for public health. Focus on the 'what', 'how', and 'why it matters' for such breakthroughs.
Remember 'Manikomycin' targets the 'E-site' like a 'Man' exiting a 'Site' (E-site).
Frequently Asked Questions
What is manikomycin and how does it work as an antibiotic?
Manikomycin is a newly discovered natural depsipeptide antibiotic from Streptomyces rimosus. It works by binding to the E-site of the bacterial large ribosomal subunit, which is crucial for protein synthesis. This unique mechanism disrupts the bacteria's ability to make proteins, thereby inhibiting its growth and survival.
Why is the discovery of manikomycin significant for fighting antibiotic resistance?
The discovery of manikomycin is significant because it represents a new class of antibiotics with a novel mechanism of action. Many existing antibiotics are becoming ineffective due to bacterial resistance. Manikomycin's unique target, the E-site, means it could be effective against bacteria that are resistant to current drugs, offering a new tool in the fight against antimicrobial resistance.
What is the E-site of a bacterial ribosome?
The E-site, or exit site, is one of three binding sites for transfer RNA (tRNA) molecules on the ribosome during protein synthesis. After a tRNA delivers its amino acid and moves from the A-site to the P-site, it then moves to the E-site before exiting the ribosome. Manikomycin targets this specific site to disrupt the process.